Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
New PlasmaDerm solution facilitates faster healing of wounds

New PlasmaDerm solution facilitates faster healing of wounds

Many people suffer from skin disorders. Open wounds are a particularly acute problem, especially among the elderly. PlasmaDerm, a new medical technology solution, uses plasma to facilitate faster healing of wounds. [More]
UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern Medical Center scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels, an important process that when abnormal can promote diabetes, cancer, and rare genetic diseases. [More]
Simon Fraser University's Maryam Sadeghi to unveil MoleScope at World Congress of Dermatology

Simon Fraser University's Maryam Sadeghi to unveil MoleScope at World Congress of Dermatology

Simon Fraser University PhD graduate Maryam Sadeghi will unveil MoleScope, an innovative hand-held tool that uses a smartphone to monitor skin for signs of cancer, at the World Congress of Dermatology conference in Vancouver June 9-13. [More]
Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis. [More]
RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA). [More]
Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience. [More]
Doctor Evidence to contribute valuable clinical data to IBM Watson's oncology solutions, developer ecosystem

Doctor Evidence to contribute valuable clinical data to IBM Watson's oncology solutions, developer ecosystem

Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem. [More]
Skin Cancer Awareness Recommended For HCT Recipients

Skin Cancer Awareness Recommended For HCT Recipients

Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say. [More]
New study examines best practices in teaching medical students to better detect skin lesions

New study examines best practices in teaching medical students to better detect skin lesions

Each year, thousands of Canadians are given the news: they have skin cancer. It is the most common form of cancer in Canada and around the world, but if detected early, survival rates are extremely high. According to Liam Rourke, it doesn't happen nearly as often as it could. [More]
Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

In what they believe to be the first survey of its kind in the United States, researchers at NYU Langone Medical Center have found that as many as 6 percent of adult New Yorkers who get "inked" — in other words, those who get a tattoo — have experienced some form of tattoo-related rash, severe itching or swelling that lasted longer than four months and, in some cases, for many years. [More]
Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults. [More]
New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists. [More]
RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today an upcoming poster presentation at the International Society for Cellular Therapy on RepliCel's autologous cell treatment for chronic Achilles tendinosis currently in a Phase 1/2 clinical trial. [More]
UBM Medica recognized with three national accolades by ASHPE

UBM Medica recognized with three national accolades by ASHPE

UBM Medica announced today that Physicians Practice, a leading online community for physicians and practice management professionals, has been recognized by the American Society of Healthcare Publication Editors with three national accolades. [More]
Full body dermatological scanner could help diagnose skin conditions in the future

Full body dermatological scanner could help diagnose skin conditions in the future

Melanoma is aggressive and life-threatening. If it is not detected early, the prospects of recovery drop. Screening is complicated, though. Together with several project partners, Fraunhofer researchers have developed an assistance system that helps dermatologists with diagnosis. [More]
UC3M, IRYCIS patent new automated skin biopsy device

UC3M, IRYCIS patent new automated skin biopsy device

Universidad Carlos III de Madrid and the Institute for Health Research of the Hospital "Ramón y Cajal" have patented a new device for performing skin biopsies. With this new tool a skin biopsy can be performed with fewer instruments and the length of the procedure is shortened from thirty minutes to less than five. [More]

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher Pharmaceuticals Inc. today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company. Both products have been approved by Health Canada. [More]
Humanized mouse model may lead to better anti-cancer therapies

Humanized mouse model may lead to better anti-cancer therapies

Human tumors grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumor is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack the foreign tumor tissue, thus allowing the tumor to grow. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
VisualDx tool aids physicians in diagnosing dermatologic conditions

VisualDx tool aids physicians in diagnosing dermatologic conditions

In the first major study to examine the use of a computer-assisted, photo-driven differential diagnosis generator for skin conditions, researchers at the Perelman School of Medicine at the University of Pennsylvania found physicians routinely used the tool, without an increase in calling for inpatient dermatology consultations. [More]
Advertisement